Smith & Nephew SNATS, Inc. $SNN Shares Bought by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC lifted its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 14.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,000 shares of the medical equipment provider’s stock after buying an additional 20,000 shares during the period. Smith & Nephew SNATS comprises 1.7% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 12th biggest holding. Sivik Global Healthcare LLC’s holdings in Smith & Nephew SNATS were worth $5,806,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Smith & Nephew SNATS by 11.7% in the 3rd quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 401 shares in the last quarter. Ashton Thomas Securities LLC grew its position in Smith & Nephew SNATS by 0.9% during the second quarter. Ashton Thomas Securities LLC now owns 55,911 shares of the medical equipment provider’s stock valued at $1,713,000 after acquiring an additional 509 shares during the period. Inspire Investing LLC increased its position in Smith & Nephew SNATS by 7.1% during the 3rd quarter. Inspire Investing LLC now owns 7,789 shares of the medical equipment provider’s stock worth $283,000 after purchasing an additional 516 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of Smith & Nephew SNATS by 15.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock valued at $118,000 after acquiring an additional 541 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in Smith & Nephew SNATS by 4.8% in the second quarter. Allspring Global Investments Holdings LLC now owns 12,462 shares of the medical equipment provider’s stock valued at $381,000 after purchasing an additional 570 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Canaccord Genuity Group lowered their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research note on Tuesday, November 11th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Monday, December 22nd. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Sanford C. Bernstein set a $37.50 price target on Smith & Nephew SNATS and gave the company a “market perform” rating in a report on Tuesday, October 14th. Finally, Royal Bank Of Canada lowered Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $35.75.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN opened at $33.89 on Wednesday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The firm has a fifty day moving average price of $33.36 and a 200 day moving average price of $34.13. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $38.79.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.